PRIME-CKD

Less pills, better pills
Personalized Drug Response:
Implementation and Evaluation in CKD

Read more ›

About Prime-CKD

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated biomarkers (i.e. signal-substances that can be measured in blood or urine) in patients with CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice.

“Individual and optimal treatment for every kidney patient; that is what we aim for.”

What is our objective?

The research project PRIME-CKD (Personalized drug Response: IMplementation and Evaluation in Chronic Kidney Disease) has a unique advantage to address the challenge we are facing as it builds on recent discoveries of new biomarkers to help guide optimal treatment to individual patients. The research must lead to new therapies for the treatment of CKD.

Read more
Objective of Prime CKD

Latest News

Annual stakeholder meeting: towards scalable, actionable biomarker use in CKD

In its third year the PRIME‑CKD consortium is making significant progress in translating biomarker research into clinical and regulatory practice for chronic kidney disease (CKD). On May 18th the consortium met with a group of stakeholders to present the progress, discuss hurdles and further steps...
Read more
, , ,

Annual meeting 2026 in Naples

In May 2026 PRIME-CKD's Annual Consortium Meeting took place in the beautiful city of Naples. The PRIME‑CKD consortium is making significant progress in translating biomarker research into clinical and regulatory practice for chronic kidney disease (CKD). The project leaders presented their progress and the group discussed...
Read more

PRIME-CKD UVALID study: crucial findings in the analytical validation of CKD biomarkers urinary epidermal growth factor (uEGF) and clusterin (uCLU)

PRIME-CKD addresses a key barrier in improving care for people with chronic kidney disease (CKD): the lack of reliable, clinically validated biomarkers to guide personalized treatment. Although CKD affects around 10% of adults worldwide and effective therapies now exist, patients respond very differently to these treatments, leaving many without optimal benefit...
Read more

Prime-CKD news in your mailbox

We can provide you with the latest information via RSS. Click the RSS icon if your browser supports RSS feeds (Chrome or addons).

Or use url https://www.prime-ckd.com/feed in a RSS-reader or an e-mail rss-feed.

Our partners

Copyright © 2024 - Webtail for UMCG Clinical Pharmacy and Pharmacology ]